Senzime Gestione

Gestione criteri di controllo 3/4

Senzime Il CEO è Philip Siberg, nominato in May2023, e ha un mandato di 1.5 anni. la retribuzione annua totale è SEK 4.61M, composta da 55.2% di stipendio e 44.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.62% delle azioni della società, per un valore di € 350.32K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 3.7 anni.

Informazioni chiave

Philip Siberg

Amministratore delegato

SEK 4.6m

Compenso totale

Percentuale dello stipendio del CEO	55.2%
Mandato del CEO	1.5yrs
Proprietà del CEO	0.6%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Philip Siberg rispetto agli utili di Senzime?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-SEK 131m
Jun 30 2024	n/a	n/a	-SEK 130m
Mar 31 2024	n/a	n/a	-SEK 131m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 134m
Sep 30 2023	n/a	n/a	-SEK 138m
Jun 30 2023	n/a	n/a	-SEK 137m
Mar 31 2023	n/a	n/a	-SEK 143m
Dec 31 2022	SEK 450k	n/a	-SEK 133m
Sep 30 2022	n/a	n/a	-SEK 114m
Jun 30 2022	n/a	n/a	-SEK 104m
Mar 31 2022	n/a	n/a	-SEK 86m
Dec 31 2021	SEK 400k	n/a	-SEK 82m
Sep 30 2021	n/a	n/a	-SEK 74m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 100k	n/a	-SEK 47m
Sep 30 2020	n/a	n/a	-SEK 41m
Jun 30 2020	n/a	n/a	-SEK 36m
Mar 31 2020	n/a	n/a	-SEK 32m
Dec 31 2019	SEK 100k	n/a	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 34m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 100k	n/a	-SEK 24m
Sep 30 2018	n/a	n/a	-SEK 19m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 13m
Dec 31 2017	SEK 131k	n/a	-SEK 13m

Compensazione vs Mercato: La retribuzione totale di Philip ($USD 417.82K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 471.14K ).

Compensazione vs guadagni: La retribuzione di Philip è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Philip Siberg (51 yo)

1.5yrs

Mandato

SEK 4,614,088

Compensazione

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Philip Siberg	Chief Executive Officer	1.5yrs	SEK 4.61m	0.62% € 350.3k
Slavoljub Grujicic	Chief Financial Officer	2.8yrs	Nessun dato	0.022% € 12.4k
Johanna Tulkki	Chief Operating Officer	4.8yrs	Nessun dato	Nessun dato
Fredrik Norrby	Chief Technology Officer	1.8yrs	Nessun dato	Nessun dato
Rianne Waninge	Application Scientist	no data	Nessun dato	Nessun dato
Paula Treutiger	Head of Communication & Investor Relations	2.8yrs	Nessun dato	Nessun dato
Anders Selin	Executive Vice President of Sales	5.2yrs	Nessun dato	Nessun dato
Michael Noble	Vice President Global Marketing	less than a year	Nessun dato	Nessun dato
Anders Jacobson	Chief Innovation Officer	8.8yrs	Nessun dato	0.014% € 7.9k
Catrin Molund	Executive Vice President of Business Development	3.8yrs	SEK 163.00k	Nessun dato
Johanna Faris	Head of Q/RA/S	less than a year	Nessun dato	0.0014% € 776.6

2.8yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 6YC è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Per Wold-Olsen	Chairman of the Board	less than a year	Nessun dato	0.56% € 316.0k
Goran Brorsson	Independent Director	1.5yrs	SEK 131.00k	0.090% € 50.4k
Adam Dahlberg	Vice Chairman of the Board	24.8yrs	SEK 350.00k	5.55% € 3.1m
Eva Walde	Independent Director	3.7yrs	SEK 210.00k	Nessun dato
Sorin Brull	Chief Medical Officer	8.8yrs	SEK 1.31m	3.33% € 1.9m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Bela Fulesdi	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Guy Cammu	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Hans Boer	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Claude Meistelman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jennifer Hunter	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Casper Claudius	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

3.7yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6YC sono considerati esperti (durata media dell'incarico 3.7 anni).

Senzime Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chairman of the Board recently bought €106k worth of stock

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Less than half of directors are independent

Recent updates

Chairman of the Board recently bought €106k worth of stock

New minor risk - Profitability

Third quarter 2024 earnings released: kr0.26 loss per share (vs kr0.33 loss in 3Q 2023)

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Second quarter 2024 earnings released

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media